{
  "id": 9418042,
  "title": "Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock",
  "url": "https://urgent.news/2026/09/23/inhibrx-biosciences-director-jon-kayyem-buys-500-000-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T21:30:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/inhibrx-biosciences-director-jon-kayyem-buys-500000-in-common-stock-93CH-4914072"
  },
  "original_language": "en",
  "account": "Inhibrx Biosciences director Jon Kayyem acquired 5,000 shares of the company's common stock for $500,000 on September 23, 2026. The stock was trading around $100 at the time of the purchase, following a substantial 247% gain over the previous year. According to InvestingPro analysis, the stock may be overvalued based on its Fair Value estimate. After this transaction, Kayyem's indirect beneficial ownership in Inhibrx Biosciences common stock is spread across multiple trusts and custodial accounts.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright lowers Anixa Biosciences stock price target to $6",
        "url": "https://urgent.news/2026/09/23/h-c-wainwright-lowers-anixa-biosciences-stock-price-target-to-6",
        "published": "2026-09-23T11:48:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}